{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:57Z","timestamp":1781639697098,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shionogi & Co., Ltd., Osaka, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This cross-sectional study explored outcomes in patients with cancer following opioid initiation (maximum observation period: 6 months), based on an analysis of laxative prescription patterns for opioid-induced constipation (OIC) using the Medical Data Vision Co., Ltd., a nationwide acute care hospital claims database in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 26,939 patients included, 16,214 (60.2%) developed OIC, defined as the prescription of a laxative on or after the fourth day following the initiation of opioid therapy. At baseline, the average age was 69.3 years, with 58.0% being male patients. Overall, 42.7% of patients were hospitalized at the time of opioid initiation (OIC subgroup: 51.1%; non-OIC subgroup: 30.1%). The majority of patients (53.9%) had observation data for less than 6 months (OIC subgroup: 61.8%; non-OIC subgroup: 42.0%). Although there were disparities in patient backgrounds and observation periods, the total healthcare costs incurred were approximately \u00a52,400,000, with \u00a52,800,000 in the OIC subgroup and \u00a51,800,000 in the non-OIC subgroup. Overall, these results highlight the importance of implementing appropriate OIC management strategies in Japan. However, it is noteworthy that the sequence of events between OIC onset and clinical outcomes remains unclear.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-026-07752-3","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T03:33:41Z","timestamp":1772681621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes in patients with cancer following opioid initiation in Japan: an exploratory study"],"prefix":"10.1186","volume":"19","author":[{"given":"Takaomi","family":"Kessoku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higashibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Oyamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7878-2557","authenticated-orcid":false,"given":"Yasuhide","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Koretaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hisanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"7752_CR1","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1089\/jpm.2021.0438","volume":"25","author":"H Mawatari","year":"2022","unstructured":"Mawatari H, Shinjo T, Morita T, Kohara H, Yomiya K. Revision of pharmacological treatment recommendations for cancer Pain: Clinical guidelines from the Japanese Society of Palliative Medicine. J Palliat Med. 2022;25:1095\u2013114.","journal-title":"J Palliat Med"},{"key":"7752_CR2","unstructured":"WHO guideline. 2019. https:\/\/www.who.int\/publications\/i\/item\/9789241550390. Accessed 24 Feb 2025."},{"key":"7752_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2050640618818305","volume":"7","author":"AD Farmer","year":"2019","unstructured":"Farmer AD, Drewes AM, Chiarioni G, De Giorgio R, O\u2019Brien T, Morlion B, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United Eur Gastroenterol J. 2019;7:7\u201320.","journal-title":"United Eur Gastroenterol J"},{"key":"7752_CR4","unstructured":"Pandey S, Goldberg JI, Haviland K. Effects of a revision to the standard admission order set on laxative prescribing for opioid-induced constipation. J Adv Pract Oncol. 2024;4:1\u201311."},{"key":"7752_CR5","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1002\/cam4.2341","volume":"8","author":"A Tokoro","year":"2019","unstructured":"Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, et al. Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study. Cancer Med. 2019;8:4883\u201391.","journal-title":"Cancer Med"},{"key":"7752_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/AJP.0b013e318237d626","volume":"28","author":"M Ishihara","year":"2012","unstructured":"Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012;28:373\u201381.","journal-title":"Clin J Pain"},{"issue":"suppl 4","key":"7752_CR7","doi-asserted-by":"publisher","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","volume":"29","author":"PJ Larkin","year":"2018","unstructured":"Larkin PJ, Cherny NI, La Carpia D, Guglielmo M, Ostgathe C, Scott\u00e9 F, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(suppl 4):iv111\u201325.","journal-title":"Ann Oncol"},{"key":"7752_CR8","doi-asserted-by":"publisher","first-page":"103876","DOI":"10.1016\/j.ijnurstu.2021.103876","volume":"115","author":"H Li","year":"2021","unstructured":"Li H, Wong CL, Jin X, Chen J, Chong YY, Bai Y. Effects of Acceptance and Commitment Therapy on health-related outcomes for patients with advanced cancer: A systematic review. Int J Nurs Stud. 2021;115:103876.","journal-title":"Int J Nurs Stud"},{"key":"7752_CR9","first-page":"e14386","volume":"13","author":"N ALMouaalamy","year":"2021","unstructured":"ALMouaalamy N. Opioid-induced constipation in advanced cancer patients. Cureus. 2021;13:e14386.","journal-title":"Cureus"},{"key":"7752_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jpainsymman.2019.11.021","volume":"59","author":"S Fumita","year":"2020","unstructured":"Fumita S, Imai H, Harada T, Noriyuki T, Gamoh M, Akashi Y, et al. Patients\u2019 self-assessment of the symptoms and impact of opioid-induced constipation: Results from a prospective observational cohort study of Japanese patients with cancer. J Pain Symptom Manage. 2020;59:1043\u201351.","journal-title":"J Pain Symptom Manage"},{"key":"7752_CR11","first-page":"687","volume":"27","author":"PG Fine","year":"2019","unstructured":"Fine PG, Chen YW, Wittbrodt E, Datto C. Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy. Support Care Cancer. 2019;27:687\u201396.","journal-title":"Support Care Cancer"},{"key":"7752_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/15360280903098440","volume":"23","author":"SD Candrilli","year":"2009","unstructured":"Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009;23:231\u201341.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"7752_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.sjpain.2017.01.006","volume":"15","author":"J S\u00f8ndergaard","year":"2017","unstructured":"S\u00f8ndergaard J, Christensen HN, Ibsen R, Jarb\u00f8l DE, Kjellberg J. Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy: A nationwide register-based cohort study in Denmark. Scand J Pain. 2017;15:83\u201390.","journal-title":"Scand J Pain"},{"key":"7752_CR14","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.jval.2011.05.019","volume":"14","author":"MLS Takemoto","year":"2011","unstructured":"Takemoto MLS, Fernandes RA, Almeida GR, Monteiro RDC, Colombini-Neto M, Bertola-Neto A. Health care resource use and costs in opioid-treated patients with and without constipation in Brazil. Value Heal. 2011;14:S78\u201381.","journal-title":"Value Heal"},{"key":"7752_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40122-023-00520-2","volume":"12","author":"T Higashibata","year":"2023","unstructured":"Higashibata T, Kessoku T, Morioka Y, Koretaka Y, Mishima H, Shibahara H, et al. A nationwide hospital claims database analysis of real-world patterns of laxative use for opioid-induced constipation in Japanese patients with cancer. Pain Ther. 2023;12:993\u20131003.","journal-title":"Pain Ther"},{"key":"7752_CR16","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3111\/13696998.2013.851082","volume":"16","author":"L Abramowitz","year":"2013","unstructured":"Abramowitz L, B\u00e9ziaud N, Labreze L, Giardina V, Causs\u00e9 C, Chuberre B, et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: A cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013;16:1423\u201333.","journal-title":"J Med Econ"},{"key":"7752_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11894-013-0344-2","volume":"15","author":"GA Ketwaroo","year":"2013","unstructured":"Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep. 2013;15:344.","journal-title":"Curr Gastroenterol Rep"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07752-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:22:52Z","timestamp":1781637772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07752-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7752"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07752-3","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized anonymized data; therefore, ethical approval and informed consent were not required per the Ethical Guidelines for Medical and Biological Research Involving Human Subjects of the Ministry of Health, Labour and Welfare of Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Takaomi Kessoku and Atsushi Nakajima have received lecture fees from Shionogi & Co., Ltd. Yasuhide Morioka and Yuichi Koretaka are employees of Shionogi & Co., Ltd. Takahiro Higashibata, Shunsuke Oyamada, Yasushi Ichikawa, and Takayuki Hisanaga have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}